Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- GENENTECH
- Filing UUID
- ed964ff1-7511-40cb-8733-f90eb9287174
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Issues related to tax exempt hospitals and charity care.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.